BamSEC and AlphaSense Join Forces
Learn More

Bioverativ Inc.

Formerly NASDAQ: BIVV
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 8 pages Severance Plan for U.S. Executive Officers
12/34/56
EX-10.1
from 10-Q 1 page October 13, 2017 John Greene 303 Columbus Avenue, Unit 1005 Boston, Ma 02116 Re: Amendment to Offer of Employment /S/ John Cox John Cox Chief Executive Officer Agreed to and Accepted By: /S/ John Greene Dated: October 14, 2017 John Greene
12/34/56
EX-10.10
from 10-K 2 pages Nonqualified Stock Option Award Agreement Granted Under Bioverativ Inc. 2017 Non-Employee Directors Equity Plan
12/34/56
EX-10.9
from 10-K 2 pages Restricted Stock Unit Award Agreement Granted Under Bioverativ Inc. 2017 Non-Employee Directors Equity Plan
12/34/56
EX-10.8
from 10-K 3 pages Nonqualified Stock Option Award Agreement Granted Under Bioverativ Inc. 2017 Omnibus Equity Plan
12/34/56
EX-10.7
from 10-K 3 pages Restricted Stock Unit Award Agreement Granted Under Bioverativ Inc. 2017 Omnibus Equity Plan
12/34/56
EX-10.6
from 8-K 14 pages Article 1 Introduction
12/34/56
EX-10.5
from 8-K 18 pages Article 1 Introduction
12/34/56
EX-10.1
from 8-K 5 pages Bioverativ Inc. 2017 Performance-Based Management Incentive Plan
12/34/56
EX-10.6
from 10-12B/A 129 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Second Amended and Restated Development and Commercialization Agreement Between Swedish Orphan Biovitrum Ab (Publ) and Biogen Idec Hemophilia Inc
12/34/56
EX-10.12
from 10-12B/A 5 pages September 28, 2016 Rogerio Vivaldi 716 Newton Street Chestnut Hill, Ma, 02467 Re: Offer of Employment Compensation and Benefits Under Employment With Biogen Prior to the Spinoff Start Date: As Agreed, Your Employment Will Commence on October 17, 2016 (Hereinafter, Your Start Date)
12/34/56
EX-10.11
from 10-12B/A 5 pages October 28, 2016 John Greene 27 Elsworthy Road London, United Kingdom, Nw3 3bt Re: Revised Offer of Employment Compensation and Benefits Under Employment With Biogen Prior to the Spinoff
12/34/56
EX-10.10
from 10-12B/A 5 pages May 19, 2016 1. Compensation and Benefits: If the Contingencies Set Forth Below Are Met, and You Become Employed by Spinco Under This Agreement, Your Employment Shall Be At-Will, and Your Compensation and Benefits Package Will Be as Follows: The Spinco Offer
12/34/56
EX-10.9
from 10-12B/A 12 pages Indemnification Agreement
12/34/56
EX-10.8
from 10-12B/A 3 pages Amendment No. 2 to Second Amended and Restated Development and Commercialization Agreement
12/34/56
EX-10.7
from 10-12B/A 4 pages Amendment No. 1 to Second Amended and Restated Development and Commercialization Agreement
12/34/56
EX-10.6
from 10-12B/A 143 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Second Amended and Restated Development and Commercialization Agreement Between Swedish Orphan Biovitrum Ab (Publ) and Biogen Idec Hemophilia Inc
12/34/56